CA2251945A1 - Antisense inhibitors of vascular endothelial growth factor (vefg/vpf) expression - Google Patents
Antisense inhibitors of vascular endothelial growth factor (vefg/vpf) expression Download PDFInfo
- Publication number
- CA2251945A1 CA2251945A1 CA002251945A CA2251945A CA2251945A1 CA 2251945 A1 CA2251945 A1 CA 2251945A1 CA 002251945 A CA002251945 A CA 002251945A CA 2251945 A CA2251945 A CA 2251945A CA 2251945 A1 CA2251945 A1 CA 2251945A1
- Authority
- CA
- Canada
- Prior art keywords
- antisense oligonucleotide
- vegf
- oligonucleotide
- oligonucleotides
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1575296P | 1996-04-17 | 1996-04-17 | |
US60/015,752 | 1996-04-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2251945A1 true CA2251945A1 (en) | 1997-10-23 |
Family
ID=21773402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002251945A Abandoned CA2251945A1 (en) | 1996-04-17 | 1997-04-17 | Antisense inhibitors of vascular endothelial growth factor (vefg/vpf) expression |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0910634A2 (ko) |
JP (1) | JP2000509259A (ko) |
KR (1) | KR20000005561A (ko) |
AU (1) | AU2733697A (ko) |
BR (1) | BR9708701A (ko) |
CA (1) | CA2251945A1 (ko) |
WO (1) | WO1997039120A2 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7238369B2 (en) | 1997-03-12 | 2007-07-03 | The Regents Of The University Of California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
US7494666B2 (en) | 1997-03-12 | 2009-02-24 | The Regents Of The University Of California | Cationic lipid compositions targeting angiogenic endothelial cells |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7423143B2 (en) | 1996-01-23 | 2008-09-09 | Affymetrix. Inc. | Nucleic acid labeling compounds |
US20010018514A1 (en) | 1998-07-31 | 2001-08-30 | Mcgall Glenn H. | Nucleic acid labeling compounds |
US6965020B2 (en) | 1996-01-23 | 2005-11-15 | Affymetrix, Inc. | Nucleic acid labeling compounds |
WO1999063975A2 (en) | 1998-06-10 | 1999-12-16 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | A method for stimulating the immune system |
EP0978561A1 (en) * | 1998-08-07 | 2000-02-09 | Hoechst Marion Roussel Deutschland GmbH | Antisense oligonucleotides for the inhibition of VEGF expression |
CN101053573A (zh) * | 2000-01-19 | 2007-10-17 | 帕卡什·S·吉尔 | 针对反义vegf寡核苷酸的方法和组合物 |
IL151928A0 (en) | 2000-03-30 | 2003-04-10 | Whitehead Biomedical Inst | Rna sequence-specific mediators of rna interference |
JP4095895B2 (ja) | 2000-12-01 | 2008-06-04 | マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー.ヴェー. | Rna干渉を媒介する短鎖rna分子 |
CA2440615A1 (en) | 2001-03-12 | 2002-09-19 | Affymetrix, Inc. | Nucleic acid labeling compounds |
WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
EP2314691A3 (en) * | 2002-11-14 | 2012-01-18 | Dharmacon, Inc. | Fuctional and hyperfunctional siRNA |
CN100371444C (zh) * | 2005-12-12 | 2008-02-27 | 清华大学深圳研究生院 | 一种抑制VEGF表达的siRNA及其应用 |
CN103301475B (zh) | 2005-12-28 | 2016-08-03 | 斯克里普斯研究所 | 药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用 |
CA2746003C (en) | 2008-12-04 | 2020-03-31 | Opko Curna, Llc | Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf |
US20110294870A1 (en) | 2008-12-04 | 2011-12-01 | Opko Curna, Llc | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
MX2011005910A (es) | 2008-12-04 | 2011-06-17 | Opko Curna Llc | Tratamiento de enfermedades relacionadas con eritropoyetina (epo) mediante inhibicion del transcrito antisentido natural a eritropoyetina. |
KR101682735B1 (ko) | 2009-02-12 | 2016-12-06 | 큐알엔에이, 인크. | 뇌 유래된 신경영양성 인자 (bdnf)에 대한 자연 안티센스 전사체의 저해에 의한 뇌 유래된 신경영양성 인자 (bdnf) 관련된 질환의 치료 |
WO2010107733A2 (en) | 2009-03-16 | 2010-09-23 | Curna, Inc. | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
CN102549159B (zh) | 2009-03-17 | 2016-08-10 | 库尔纳公司 | 通过抑制针对δ样1同源物(DLK1)的天然反义转录物来治疗DLK1相关的疾病 |
KR101835889B1 (ko) | 2009-05-06 | 2018-03-08 | 큐알엔에이, 인크. | 지질 수송 및 대사 유전자에 대한 천연 안티센스 전사체의 억제에 의해 지질 수송 및 대사 유전자 관련된 질환의 치료 |
CA2761142C (en) | 2009-05-06 | 2021-06-08 | Opko Curna, Llc | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
US9012139B2 (en) | 2009-05-08 | 2015-04-21 | Curna, Inc. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family |
DK2432881T3 (en) | 2009-05-18 | 2018-02-26 | Curna Inc | TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR |
WO2010135695A2 (en) | 2009-05-22 | 2010-11-25 | Curna, Inc. | TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3 |
CN103221541B (zh) | 2009-05-28 | 2017-03-01 | 库尔纳公司 | 通过抑制抗病毒基因的天然反义转录物来治疗抗病毒基因相关疾病 |
JP5944311B2 (ja) | 2009-06-16 | 2016-07-05 | クルナ・インコーポレーテッド | コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療 |
ES2629339T3 (es) | 2009-06-16 | 2017-08-08 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1 |
CA2765889A1 (en) | 2009-06-24 | 2010-12-29 | Opko Curna, Llc | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
KR101807324B1 (ko) | 2009-06-26 | 2017-12-08 | 큐알엔에이, 인크. | 다운 증후군 유전자에 대한 천연 안티센스 전사체의 억제에 의한 다운 증후군 유전자 관련된 질환의 치료 |
CA2768947C (en) | 2009-07-24 | 2018-06-19 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
WO2011017516A2 (en) | 2009-08-05 | 2011-02-10 | Curna, Inc. | Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) |
EP2464731B1 (en) | 2009-08-11 | 2016-10-05 | CuRNA, Inc. | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
EP2982755B1 (en) | 2009-08-21 | 2020-10-07 | CuRNA, Inc. | Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip |
EP2470657B1 (en) | 2009-08-25 | 2019-10-23 | CuRNA, Inc. | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
DK2480669T3 (en) | 2009-09-25 | 2018-02-12 | Curna Inc | TREATMENT OF FILAGGRIN- (FLG) RELATED DISEASES BY MODULATING FLG EXPRESSION AND ACTIVITY |
CA2782366A1 (en) | 2009-12-16 | 2011-07-14 | Opko Curna, Llc | Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1 |
US9068183B2 (en) | 2009-12-23 | 2015-06-30 | Curna, Inc. | Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2 |
WO2011079261A2 (en) | 2009-12-23 | 2011-06-30 | Curna, Inc. | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
RU2611186C2 (ru) | 2009-12-29 | 2017-02-21 | Курна, Инк. | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С ОПУХОЛЕВЫМ БЕЛКОМ 63 (р63), ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К р63 |
EP2519633B1 (en) | 2009-12-29 | 2017-10-25 | CuRNA, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
RU2016115782A (ru) | 2009-12-31 | 2018-11-28 | Курна, Инк. | Лечение заболеваний, связанных с субстратом рецептора инсулина 2 (irs2), путем ингибирования природного антисмыслового транскрипта к irs2 и транскрипционному фактору е3 (tfe3) |
US8946181B2 (en) | 2010-01-04 | 2015-02-03 | Curna, Inc. | Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8 |
WO2011085066A2 (en) | 2010-01-06 | 2011-07-14 | Curna, Inc. | Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene |
EP2524039B1 (en) | 2010-01-11 | 2017-11-29 | CuRNA, Inc. | Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg |
RU2611192C2 (ru) | 2010-01-25 | 2017-02-21 | Курна, Инк. | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С РНКазой Н1, ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К РНКазе Н1 |
KR101838308B1 (ko) | 2010-02-22 | 2018-03-13 | 큐알엔에이, 인크. | 피롤린-5-카르복실레이트 환원효소 1(pycr1)에 대한 천연 안티센스 전사체의 억제에 의한 pycr1과 관련된 질환의 치료 |
US8980856B2 (en) | 2010-04-02 | 2015-03-17 | Curna, Inc. | Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3 |
RU2610661C2 (ru) | 2010-04-09 | 2017-02-14 | Курна, Инк. | Лечение заболеваний, связанных с фактором роста фибробластов 21 (fgf21), путем ингибирования природного антисмыслового транскрипта к fgf21 |
RU2693462C2 (ru) | 2010-05-03 | 2019-07-03 | Курна, Инк. | Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt) |
TWI586356B (zh) | 2010-05-14 | 2017-06-11 | 可娜公司 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
EP2576783B1 (en) | 2010-05-26 | 2017-11-29 | CuRNA, Inc. | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
JP5917497B2 (ja) | 2010-05-26 | 2016-05-18 | カッパーアールエヌエー,インコーポレイテッド | メチオニンスルホキシドレダクターゼa(msra)に対する天然アンチセンス転写物の阻害によるmsra関連疾患の治療 |
JP6023705B2 (ja) | 2010-06-23 | 2016-11-09 | カッパーアールエヌエー,インコーポレイテッド | ナトリウムチャネル、電位依存性、αサブユニット(SCNA)に対する天然アンチセンス転写物の阻害によるSCNA関連疾患の治療 |
JP5998131B2 (ja) | 2010-07-14 | 2016-09-28 | カッパーアールエヌエー,インコーポレイテッド | Discslargehomolog(dlg)dlg1への天然アンチセンス転写物の阻害によるdlg関連疾患の治療 |
WO2012015775A2 (en) | 2010-07-28 | 2012-02-02 | Dharmacon, Inc. | Sirna targeting vegfa and methods for treatment in vivo |
ES2640755T3 (es) | 2010-10-06 | 2017-11-06 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la Sialidasa 4 (neu4) mediante inhibición del transcrito antisentido natural al gen neu4 |
EP2630241B1 (en) | 2010-10-22 | 2018-10-17 | CuRNA, Inc. | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
WO2012068340A2 (en) | 2010-11-18 | 2012-05-24 | Opko Curna Llc | Antagonat compositions and methods of use |
US8987225B2 (en) | 2010-11-23 | 2015-03-24 | Curna, Inc. | Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG |
ES2653247T3 (es) | 2011-06-09 | 2018-02-06 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la frataxina (FXN) mediante inhibición del transcrito antisentido natural al gen FXN |
CN108272782B (zh) | 2011-09-06 | 2021-04-23 | 库尔纳公司 | 小分子在制备治疗Dravet综合征或全面性癫痫伴热性惊厥附加症的药物中的用途 |
US20150031750A1 (en) | 2012-03-15 | 2015-01-29 | The Scripps Research Institute | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
WO2020109344A1 (en) | 2018-11-29 | 2020-06-04 | F. Hoffmann-La Roche Ag | Occular administration device for antisense oligonucleotides |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9106702A (pt) * | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals Inc | Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo |
US5484908A (en) * | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
DE637965T1 (de) * | 1991-11-26 | 1995-12-14 | Gilead Sciences Inc | Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen. |
US6410322B1 (en) * | 1993-07-27 | 2002-06-25 | Hybridon Inc | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression |
US5731294A (en) * | 1993-07-27 | 1998-03-24 | Hybridon, Inc. | Inhibition of neovasularization using VEGF-specific oligonucleotides |
WO1996000286A1 (fr) * | 1994-06-27 | 1996-01-04 | Toagosei Co., Ltd. | Compose d'acide nucleique antisens |
DE19502912A1 (de) * | 1995-01-31 | 1996-08-01 | Hoechst Ag | G-Cap Stabilisierte Oligonucleotide |
-
1997
- 1997-04-17 EP EP97921238A patent/EP0910634A2/en not_active Withdrawn
- 1997-04-17 WO PCT/US1997/006412 patent/WO1997039120A2/en not_active Application Discontinuation
- 1997-04-17 KR KR1019980708435A patent/KR20000005561A/ko not_active Application Discontinuation
- 1997-04-17 AU AU27336/97A patent/AU2733697A/en not_active Abandoned
- 1997-04-17 JP JP9537367A patent/JP2000509259A/ja active Pending
- 1997-04-17 BR BR9708701-7A patent/BR9708701A/pt not_active Application Discontinuation
- 1997-04-17 CA CA002251945A patent/CA2251945A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7238369B2 (en) | 1997-03-12 | 2007-07-03 | The Regents Of The University Of California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
US7494666B2 (en) | 1997-03-12 | 2009-02-24 | The Regents Of The University Of California | Cationic lipid compositions targeting angiogenic endothelial cells |
Also Published As
Publication number | Publication date |
---|---|
JP2000509259A (ja) | 2000-07-25 |
KR20000005561A (ko) | 2000-01-25 |
WO1997039120A2 (en) | 1997-10-23 |
BR9708701A (pt) | 2000-01-04 |
EP0910634A2 (en) | 1999-04-28 |
WO1997039120A3 (en) | 1998-02-19 |
AU2733697A (en) | 1997-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2251945A1 (en) | Antisense inhibitors of vascular endothelial growth factor (vefg/vpf) expression | |
JP3231779B2 (ja) | raf遺伝子発現のアンチセンスオリゴヌクレオチド調節 | |
RU2399671C2 (ru) | Способный к интерференции дуплекс рнк, имеющий "тупые" концы и 3'-модификации | |
CN108064154B (zh) | 用于抑制hao1(羟酸氧化酶1(乙醇酸盐氧化酶))基因表达的组合物及方法 | |
JP3054745B2 (ja) | raf遺伝子発現のアンチセンスオリゴヌクレオチド調節 | |
TWI231312B (en) | Novel dumbbell decoy oligodeoxynucleotides and use thereof | |
CA2207593A1 (en) | Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses | |
JP2009000105A (ja) | 短干渉核酸(siNA)を用いた血管内皮成長因子および血管内皮成長因子レセプター遺伝子発現のRNA干渉媒介阻害 | |
IL195181A (en) | Compositions for inhibiting the expression of the pcsk9 gene | |
JPH10508181A (ja) | リボヌクレアーゼp標的化および切断配列を用いるrnaの標的化切断 | |
JP2001511003A (ja) | 表皮成長因子レセプターのレベルに関連した疾患または病状の酵素的核酸治療 | |
Ma et al. | Synthetic oligonucleotides as therapeutics: the coming of age | |
JP2003524637A (ja) | Lna修飾オリゴヌクレオチドの治療上の使用 | |
IL293434B1 (en) | RNAI factors, compositions and methods of using them for the treatment of transthyretin-related diseases | |
AU2003213150A2 (en) | Method of using modified oligonucleotides for hepatic delivery | |
CA2205075C (en) | Reagent and method for inhibition of n-ras expression | |
US6001991A (en) | Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression | |
JP2012528597A (ja) | 血小板グリコプロテインviの核酸調節因子 | |
Hélin et al. | Cell cycle-dependent distribution and specific inhibitory effect of vectorized antisense oligonucleotides in cell culture | |
JP2003505517A (ja) | 接合体ならびにそれらの製造方法および生体膜を横切り分子を輸送するためのそれらの使用 | |
WO2014066142A1 (en) | Nucleic acid regulation of growth arrest-specific protein 6 (gas6) | |
Rubenstein et al. | A review of antisense oligonucleotides in the treatment of human disease | |
CA2223109A1 (en) | Use of antisense oligonucleotides to il-6 receptor mrna to inhibit cellular proliferation | |
JP2000506866A (ja) | アンギオテンシノゲンmRNAに標的化されたオリゴヌクレオチド | |
Holasová et al. | Cholesterol conjugated oligonucleotide and LNA: a comparison of cellular and nuclear uptake by Hep2 cells enhanced by streptolysin-O |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |